Overview Dividends

(RPRX) Royalty Pharma - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: GB00BMVP7Y09

Royalties, Biopharma, Investments, Therapies

Pharmaceuticals
Market Cap in USD: 22,341m

IPO / Inception: 1993-03-25
Return 12m vs S&P 500: 35.4%

EPS (Earnings per Share)

EPS CAGR: 10.67%
EPS Trend: 42.1%

Last SUE: 0.77
Qual. Beats: 0

Revenue

Rev. CAGR: 1.52%
Rev. Trend: 14.3%

Last SUE: -1.00
Qual. Beats: 0

Dividends

Dividend Yield	2.26%
Yield on Cost 5y	2.02%
Yield CAGR 5y	29.36%
Payout Consistency	100.0%
Payout Ratio	23.7%

Risk via 5d forecast
Volatility	22.7%
Value at Risk 5%th	35.5%
Relative Tail Risk	-4.81%

Reward TTM
Sharpe Ratio	1.88
Alpha	54.46
CAGR/Max DD	0.06

Character TTM
Hurst Exponent	0.262
Beta	0.288
Beta Downside	0.129

Drawdowns 3y
Max DD	35.05%
Mean DD	17.64%
Median DD	20.59%

Description: RPRX Royalty Pharma December 19, 2025

Royalty Pharma plc (NASDAQ:RPRX) purchases biopharmaceutical royalty streams and provides financing to U.S. drug developers, positioning itself as a pure-play royalty fund rather than a traditional pharma operator.

Its current portfolio contains royalty rights on roughly 35 commercially launched therapies and 14 late-stage development candidates spanning rare diseases, oncology, neuroscience, infectious disease, hematology, and diabetes, offering diversification across therapeutic areas and development phases.

Key metrics as of the latest filing show a market-adjusted enterprise value of about $2.4 billion, a dividend yield near 5 %, and cash-flow coverage of royalty payments exceeding 3×, while the broader biotech royalty market is expanding at a 12-15 % CAGR driven by increasing R&D spend and a wave of patent expirations that create new royalty opportunities.

For a deeper quantitative assessment, consider reviewing ValueRay’s analyst tools to model royalty cash-flow sensitivity under different discount rates and pipeline success scenarios.

Piotroski VR‑10 (Strict, 0-10) 5.0

Net Income (765.0m TTM) > 0 and > 6% of Revenue (6% = 141.0m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA -3.08pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 56.12% (prev 27.65%; Δ 28.48pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 2.41b > Net Income 765.0m (YES >=105%, WARN >=100%)

Net Debt (8.03b) to EBITDA (1.58b) ratio: 5.07 <= 3.0 (WARN <= 3.5)

Current Ratio 3.48 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (559.6m) change vs 12m ago -5.63% (target <= -2.0% for YES)

Gross Margin 78.88% (prev 60.56%; Δ 18.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 12.57% (prev 12.56%; Δ 0.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 5.83 (EBITDA TTM 1.58b / Interest Expense TTM 279.3m) >= 6 (WARN >= 3)

Altman Z'' 1.67

(A) 0.07 = (Total Current Assets 1.85b - Total Current Liabilities 530.8m) / Total Assets 19.35b

(B) 0.12 = Retained Earnings (Balance) 2.30b / Total Assets 19.35b

(D) 0.24 = Book Value of Equity 2.30b / Total Liabilities 9.73b

Total Rating: 1.67 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 59.71

1. Piotroski 5.0pt

2. FCF Yield 7.93%

3. FCF Margin data missing

4. Debt/Equity 1.40

5. Debt/Ebitda 5.07

6. ROIC - WACC (= 2.00)%

7. RoE 11.59%

8. Rev. Trend 14.34%

9. EPS Trend 42.09%

What is the price of RPRX shares?

As of December 23, 2025, the stock is trading at USD 38.86 with a total of 2,145,169 shares traded.
Over the past week, the price has changed by +0.86%, over one month by -2.24%, over three months by +8.97% and over the past year by +57.78%.

Is RPRX a buy, sell or hold?

Royalty Pharma has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy RPRX.

Strong Buy: 4
Buy: 2
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the RPRX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	46.3	19.2%
Analysts Target Price	46.3	19.2%
ValueRay Target Price	46.3	19.1%

RPRX Fundamental Data Overview December 19, 2025

Market Cap USD = 22.34b (22.34b USD * 1.0 USD.USD)
P/E Trailing = 21.8914
P/E Forward = 11.3766
P/S = 9.5076
P/B = 2.5571
P/EG = 1.6902
Beta = 0.46
Revenue TTM = 2.35b USD
EBIT TTM = 1.63b USD
EBITDA TTM = 1.58b USD
Long Term Debt = 8.57b USD (from longTermDebt, last quarter)
Short Term Debt = 383.1m USD (from shortTermDebt, last quarter)
Debt = 8.97b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.03b USD (from netDebt column, last quarter)
Enterprise Value = 30.35b USD (22.34b + Debt 8.97b - CCE 955.0m)
Interest Coverage Ratio = 5.83 (Ebit TTM 1.63b / Interest Expense TTM 279.3m)
FCF Yield = 7.93% (FCF TTM 2.41b / Enterprise Value 30.35b)
FCF Margin = 102.4% (FCF TTM 2.41b / Revenue TTM 2.35b)
Net Margin = 32.55% (Net Income TTM 765.0m / Revenue TTM 2.35b)
Gross Margin = 78.88% ((Revenue TTM 2.35b - Cost of Revenue TTM 496.4m) / Revenue TTM)
Gross Margin QoQ = 99.79% (prev 64.76%)
Tobins Q-Ratio = 1.57 (Enterprise Value 30.35b / Total Assets 19.35b)
Interest Expense / Debt = 0.89% (Interest Expense 79.6m / Debt 8.97b)
Taxrate = 35.12% (156.0m / 444.2m)
NOPAT = 1.06b (EBIT 1.63b * (1 - 35.12%))
Current Ratio = 3.48 (Total Current Assets 1.85b / Total Current Liabilities 530.8m)
Debt / Equity = 1.40 (Debt 8.97b / totalStockholderEquity, last quarter 6.41b)
Debt / EBITDA = 5.07 (Net Debt 8.03b / EBITDA 1.58b)
Debt / FCF = 3.34 (Net Debt 8.03b / FCF TTM 2.41b)
Total Stockholder Equity = 6.60b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.95% (Net Income 765.0m / Total Assets 19.35b)
RoE = 11.59% (Net Income TTM 765.0m / Total Stockholder Equity 6.60b)
RoCE = 10.74% (EBIT 1.63b / Capital Employed (Equity 6.60b + L.T.Debt 8.57b))
RoIC = 7.22% (NOPAT 1.06b / Invested Capital 14.64b)
WACC = 5.22% (E(22.34b)/V(31.31b) * Re(7.08%) + D(8.97b)/V(31.31b) * Rd(0.89%) * (1-Tc(0.35)))
Discount Rate = 7.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 33.33 | Cagr: 11.94%
[DCF Debug] Terminal Value 78.58% ; FCFE base≈2.56b ; Y1≈2.61b ; Y5≈2.89b
Fair Price DCF = 119.1 (DCF Value 50.88b / Shares Outstanding 427.2m; 5y FCF grow 1.81% → 3.0% )
EPS Correlation: 42.09 | EPS CAGR: 10.67% | SUE: 0.77 | # QB: 0
Revenue Correlation: 14.34 | Revenue CAGR: 1.52% | SUE: -1.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.15 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=5.05 | Chg30d=+0.008 | Revisions Net=+0 | Growth EPS=+8.9% | Growth Revenue=+3.7%

Additional Sources for RPRX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle